Panel: Investor’s Scienter Allegations Missed The Mark In Stock-Drop Suit
NEW YORK — A federal district court did not err in dismissing lead plaintiffs’ second amended complaint against a generic drug maker and certain of its current and former senior executives...To view the full article, register now.
Already a subscriber? Click here to view full article